News Image

Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine

Provided By GlobeNewswire

Last update: Jul 9, 2025

The previously disclosed and now published RESILIENT data show that once-nightly TNX-102 SL achieved statistically significant improvement in the primary endpoint of reducing fibromyalgia pain versus placebo, and was generally well tolerated

Read more at globenewswire.com

TONIX PHARMACEUTICALS HOLDIN

NASDAQ:TNXP (7/25/2025, 3:36:07 PM)

49.31

+4.59 (+10.26%)



Find more stocks in the Stock Screener

Follow ChartMill for more